Medical Devices Reimbursement Market Growth Analysis, Key Trends & Forecast, 2026-2035
The global medical devices reimbursement market is valued at USD 891.7 billion in 2026, with the market estimated to reach USD 948.6 billion in 2027 and projected to expand to USD 1.84 trillion by 2036, reflecting a 7.51% CAGR from 2027 to 2036. This expansion is being shaped by the growing complexity of medical-device claims, wider use of advanced technologies, and the need for healthcare providers and manufacturers to secure appropriate payment for reimbursable products and services. As reimbursement frameworks become more closely linked to clinical outcomes, coding accuracy, coverage requirements, and utilization management, reimbursement is increasingly becoming a strategic component of medical-device commercialization rather than a purely administrative activity.
The strongest momentum is visible in underpaid claims, where organizations need specialized processes to identify payment gaps, review claim details, and recover revenue that may otherwise remain uncollected. This creates demand for reimbursement management capabilities that combine claims expertise with knowledge of payer policies and device-specific reimbursement pathways.
The shift toward value-based healthcare is also changing how stakeholders evaluate medical technologies. Reimbursement decisions are increasingly connected to patient outcomes and healthcare value, encouraging manufacturers and providers to demonstrate clinical and economic benefits alongside technological performance. For the industry, this creates opportunities for organizations that can connect device adoption, documentation, coding, coverage, and payment outcomes into a more integrated reimbursement strategy.
Regional Analysis: North America Leads While Asia Pacific Builds Growth Momentum
North America remains the leading regional market, supported by mature reimbursement systems, broad insurance coverage, and structured coding pathways. These characteristics create a comparatively established environment for medical-device adoption, while also increasing the importance of accurate claims management. The region's sophisticated payer-provider relationships generate demand for specialized reimbursement expertise, particularly where device coverage involves detailed documentation, coding, and payment requirements.
By contrast, Asia Pacific is emerging as the high-growth regional hub, supported by expanding healthcare access, deeper insurance penetration, and increasing adoption of advanced medical devices across evolving healthcare systems. The region's opportunity is linked not simply to rising healthcare expenditure but also to the gradual development of reimbursement structures capable of supporting more sophisticated medical technologies.
The difference between the regions creates distinct strategic priorities. In North America, market participants can focus on improving revenue recovery, navigating complex payer requirements, and optimizing existing reimbursement processes. In Asia Pacific, the opportunity is more closely associated with healthcare-system development, insurance expansion, and the establishment of reimbursement mechanisms capable of supporting broader medical-device access.
For manufacturers and reimbursement service providers, this regional contrast suggests that a single commercialization model may not be sufficient. Mature markets require greater reimbursement optimization, while developing markets require stronger attention to coverage structures, payer development, and local healthcare-system requirements.
Industry Challenge: Reimbursement Complexity Can Slow Medical-Device Adoption
One of the industry's central challenges is the growing complexity of securing appropriate reimbursement for advanced medical devices. A technologically effective device does not automatically translate into predictable payment. Coverage conditions, coding requirements, payer policies, documentation standards, and clinical evidence can all influence whether a claim is reimbursed appropriately.
This challenge becomes particularly significant for devices used in chronic disease management and complex clinical settings. As healthcare providers adopt increasingly sophisticated technologies, reimbursement processes must accommodate more detailed clinical and utilization information. Any disconnect between clinical documentation and reimbursement requirements can create delayed, reduced, or missed payments.
The growth of underpaid claims highlights another commercial constraint. Identifying these claims requires dedicated review processes and reimbursement expertise, making it difficult for organizations with limited internal resources to capture all potential revenue. The issue is therefore not simply administrative inefficiency; it can influence the financial sustainability of adopting and providing advanced technologies.
The transition toward value-based healthcare adds another layer of complexity. Providers and payers increasingly need reimbursement arrangements that reflect outcomes rather than relying exclusively on traditional fee-for-service structures. Medical-device companies may consequently need to demonstrate not only clinical performance but also the broader economic and patient-value proposition of their technologies.
Segment Comparison: Underpaid Claims and Private Payers Address Different Reimbursement Needs
The underpaid claims segment represents an important area of reimbursement management because it focuses on recovering revenue that has already entered the claims process but has not been fully reimbursed. Its importance stems from the specialized expertise required to identify payment discrepancies, interpret reimbursement rules, and pursue appropriate recovery.
Private payers, meanwhile, represent a different type of opportunity. Commercial insurance arrangements can involve varying plan policies, coverage conditions, contractual structures, and payment outcomes. This variability increases the need for specialized claims expertise and revenue-recovery capabilities.
The distinction between the two segments is strategically important. Underpaid claims are primarily associated with revenue optimization and recovery, while private-payer activity is closely connected with payer complexity and coverage variation. Both require strong reimbursement knowledge, but the operational priorities can differ.
For reimbursement service providers, this creates opportunities to develop specialized capabilities across the claims lifecycle. For medical-device manufacturers, understanding these differences can help inform payer engagement, market-access strategies, contracting approaches, and post-market reimbursement support.
As reimbursement becomes more closely tied to clinical value and real-world outcomes, both areas are likely to require stronger coordination between claims administration, clinical evidence, coding, and payer relationships.
Geographic Opportunity: Healthcare-System Development Creates New Reimbursement Markets
Several geographic markets offer strategic relevance because healthcare access, insurance coverage, and medical-technology adoption are evolving simultaneously.
- United States: The market benefits from mature reimbursement infrastructure, extensive insurance coverage, established coding systems, and significant adoption of advanced medical devices. Opportunities center on reimbursement optimization, claims recovery, payer management, and value-based contracting.
- Canada: Its established healthcare environment provides a relevant market for medical technologies that require structured coverage and reimbursement pathways. Market participants need to understand the relationship between healthcare access, public-sector coverage, and device evaluation.
- China: Expanding healthcare access and continued adoption of advanced medical technologies create opportunities as reimbursement structures evolve. Manufacturers and service providers can benefit from developing localized market-access and reimbursement strategies.
- India: Expanding healthcare access and increasing adoption of advanced medical technologies create longer-term opportunities for reimbursement infrastructure and specialized claims management. Greater insurance penetration can support wider access to reimbursable technologies while increasing the need for organized reimbursement processes.
Across these markets, the commercial opportunity depends on more than device demand. Successful market entry increasingly requires an understanding of how coverage decisions, payer structures, clinical evidence, and reimbursement administration interact.
Competitive Landscape: Companies Are Expanding Beyond Traditional Device and Insurance Roles
The competitive landscape spans healthcare analytics, insurance, medical technology, provider services, and reimbursement management. Key participants include IQVIA Holdings Inc., Humana Inc., The Cigna Group, Elevance Health, Abbott Laboratories, Boston Scientific Corporation, Johnson & Johnson, UnitedHealth Group Incorporated, Medtronic plc, and AdvaMed.
Their activities illustrate how reimbursement is becoming increasingly connected with broader healthcare strategies. Insurers and healthcare organizations are experimenting with outcomes-oriented contracting and integrated management approaches, while medical-device companies operate in an environment where market access increasingly depends on reimbursement evidence and payer engagement.
Recent activity involving UnitedHealth Group demonstrates the movement toward outcomes-based reimbursement contracts for implantable cardiac defibrillators and cardiac resynchronization therapy. Such arrangements connect manufacturer reimbursement with real-world clinical outcomes and reinforce the wider transition toward value-based procurement.
Humana has also pursued value-based procurement partnerships involving durable medical equipment providers, illustrating how reimbursement and equipment acquisition can become integrated into broader healthcare-management strategies.
Meanwhile, the presence of major device manufacturers alongside payers and healthcare analytics companies indicates that competitive differentiation increasingly extends beyond the physical medical device. Expertise in evidence generation, claims management, payer engagement, utilization, and reimbursement strategy can influence how technologies reach patients and generate sustainable commercial returns.
Recent Industry News: Reimbursement Policies and Value-Based Models Reshape Market Direction
Recent industry developments demonstrate that reimbursement is becoming more closely connected with coverage policy, clinical outcomes, and integrated healthcare management.
August 2025 — Centers for Medicare & Medicaid Services
The Centers for Medicare & Medicaid Services issued a National Coverage Determination establishing reimbursement for implantable pulmonary artery pressure sensors under the Coverage with Evidence Development framework. The decision formally approved the CardioMEMS study and expanded standardized coverage for eligible Medicare beneficiaries.
The development illustrates how regulatory and coverage decisions can directly influence medical-device access. Evidence-based coverage mechanisms can provide manufacturers with a clearer route toward reimbursement while allowing healthcare systems to evaluate clinical outcomes within defined frameworks.
November 2025 — UnitedHealth Group
UnitedHealth Group launched structured outcomes-based reimbursement contracts covering implantable cardiac defibrillators and cardiac resynchronization therapy. The approach links manufacturer reimbursement to real-world patient clinical outcomes.
This development reflects a broader movement away from reimbursement models based solely on device utilization. Connecting payment with outcomes may encourage stronger evidence generation and closer collaboration among manufacturers, payers, and healthcare providers.
September 2025 — CVS Health
CVS Health introduced an integrated diabetes-management infrastructure combining continuous glucose monitor reimbursement with clinical pharmacy services and predictive analytics. The approach demonstrates how reimbursement for connected monitoring technologies can increasingly become part of a broader digital-health ecosystem.
Such integration can help align device utilization with patient management, clinical services, and data-driven decision-making rather than treating reimbursement as an isolated administrative process.
February 2025 — French National Authority for Health
The French National Authority for Health issued structural recommendations regarding add-on device coverage within the national List of Reimbursable Products and Services. The framework updates clinical evaluation methodologies and pricing structures across multiple device sectors.
The development highlights the importance of regulatory and reimbursement frameworks in determining market-entry conditions. Changes to evaluation and pricing mechanisms can influence both manufacturers' commercialization strategies and healthcare providers' access to medical technologies.
May 2023 — Humana
Humana established regional value-based procurement partnerships with national durable medical equipment providers, including AdaptHealth Corp. and Rotech Healthcare Inc. The initiative focused on optimizing device distribution and acquisition for Medicare Advantage members while moving equipment reimbursement away from traditional fee-for-service frameworks.
Although earlier than the other developments, the initiative remains relevant because it demonstrates the structural direction of reimbursement toward value-based procurement and more integrated equipment-management models.
Read more about this report @ https://www.fundamentalbusinessinsights.com/industry-report/medical-devices-reimbursement-market-3283
About Fundamental Business Insights:
Fundamental Business Insights is global market research and consulting company which is engaged in providing in depth market reports to its various types of clients like industrial sectors, financial sectors, universities, non-profit, and corporations. Our goal is to offer the correct information to the right stakeholder at the right time, in a format that enables logical and informed decision making. We have a team of consultants who have experience in offering executive level blueprints of markets and solutions. Our services include syndicated market studies, customized research reports, and consultation.
Contact us:
Robbin Fernandez
Head of Business Development
Fundamental Business Insights and Consulting
Email: sales@fundamentalbusinessinsights.com
Read This Report in Regional Languages -
